• Wiley Online Library will be disrupted on 26 May from 10:00-12:00 BST (05:00-07:00 EDT) for essential maintenance

Original Article

You have full text access to this OnlineOpen article

Elevated serum levels of IGF-1 are sufficient to establish normal body size and skeletal properties even in the absence of tissue IGF-1

  1. Sebastien Elis1,
  2. Hayden-William Courtland1,
  3. Yingjie Wu1,
  4. Clifford J Rosen2,
  5. Hui Sun1,
  6. Karl J Jepsen3,
  7. Robert J Majeska4,
  8. Shoshana Yakar1,*

Article first published online: 14 JAN 2010

DOI: 10.1002/jbmr.20

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 6, pages 1257–1266, June 2010

Additional Information

How to Cite

Elis, S., Courtland, H.-W., Wu, Y., Rosen, C. J., Sun, H., Jepsen, K. J., Majeska, R. J. and Yakar, S. (2010), Elevated serum levels of IGF-1 are sufficient to establish normal body size and skeletal properties even in the absence of tissue IGF-1. J Bone Miner Res, 25: 1257–1266. doi: 10.1002/jbmr.20

Author Information

  1. 1

    Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, New York, NY, USA

  2. 2

    Maine Medical Center Research Institute, Scarborough, ME, USA

  3. 3

    Leni and Peter W May Department of Orthopaedics, Mount Sinai School of Medicine, New York, NY, USA

  4. 4

    Department of Biomedical Engineering, City College of New York, New York, NY, USA

*Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1055, New York, NY 10029-6574, USA.

Publication History

  1. Issue published online: 27 MAY 2010
  2. Article first published online: 14 JAN 2010
  3. Accepted manuscript online: 14 JAN 2010 12:00AM EST
  4. Manuscript Accepted: 29 DEC 2009
  5. Manuscript Revised: 19 NOV 2009
  6. Manuscript Received: 28 JUL 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (338K)

References

  • 1
    Silha JV, Murphy LJ. Insulin-like growth factor binding proteins in development. Adv Exp Med Biol. 2005; 567: 55–89.
  • 2
    Daughaday WH. Growth hormone axis overview: somatomedin hypothesis. Pediatr Nephrol. 2000; 14: 537–40.
  • 3
    Isaksson O, Ohlsson C, Sjogren K, Wallenius K, Jansson JO. The somatomedin hypothesis revisited in a transgenic model. Growth Horm IGF Res. 2001; 11 (Suppl A): S49–52.
  • 4
    Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev. 2001; 22: 53–74.
  • 5
    Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol. 2001; 229: 141–62.
  • 6
    Mohan S, Richman C, Guo R, et al. Insulin-like growth factor regulates peak bone mineral density in mice by both growth hormone-dependent and -independent mechanisms. Endocrinology. 2003; 144: 929–36.
  • 7
    Efstratiadis A. Genetics of mouse growth. Int J Dev Biol. 1998; 42: 955–76.
  • 8
    Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993; 75: 73–82.
  • 9
    Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell. 1993; 75: 59–72.
  • 10
    Yakar S, Canalis E, Sun H, et al. Serum IGF-1 Determines Skeletal Strength by Regulating Sub-Periosteal Expansion and Trait Interactions. J Bone Miner Res. 2009.
    Direct Link:
  • 11
    Backeljauw PF, Underwood LE. Therapy for 6. 5–7. 5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metab. 2001; 86: 1504–10.
  • 12
    Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab. 2007; 92: 902–10.
  • 13
    Guevara-Aguirre J, Rosenbloom AL, Vasconez O, et al. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency. J Clin Endocrinol Metab. 1997; 82: 629–33.
  • 14
    Klinger B, Laron Z. Three year IGF-I treatment of children with Laron syndrome. J Pediatr Endocrinol Metab. 1995; 8: 149–58.
  • 15
    Ranke MB, Savage MO, Chatelain PG, et al. Insulin-like growth factor I improves height in growth hormone insensitivity: two years' results. Horm Res. 1995; 44: 253–64.
  • 16
    Sims NA, Clement-Lacroix P, Da Ponte F, et al. Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest. 2000; 106: 1095–103.
  • 17
    Wu Y, Sun H, Yakar S, Leroith D. Elevated levels of IGF-1 in serum rescue the severe growth retardation of IGF-1 null mice. Endocrinology. 2009.
  • 18
    Yakar S, Bouxsein ML, Canalis E, et al. The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. J Endocrinol. 2006; 189: 289–99.
  • 19
    Yakar S, Rosen CJ, Beamer WG, et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002; 110: 771–81.
  • 20
    Yakar S, Setser J, Zhao H, et al. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest. 2004; 113: 96–105.
  • 21
    Jepsen KJ, Hu B, Tommasini SM, et al. Genetic randomization reveals functional relationships among morphologic and tissue-quality traits that contribute to bone strength and fragility. Mamm Genome. 2007; 18: 492–507.
  • 22
    Barron M, McAllister D, Smith SM, Lough J. Expression of retinol binding protein and transthyretin during early embryogenesis. Dev Dyn. 1998; 212: 413–22.
    Direct Link:
  • 23
    Makover A, Soprano DR, Wyatt ML, Goodman DS. An in situ-hybridization study of the localization of retinol-binding protein and transthyretin messenger RNAs during fetal development in the rat. Differentiation. 1989; 40: 17–25.
    Direct Link:
  • 24
    Soprano DR, Soprano KJ, Wyatt ML, Goodman DS. Induction of the expression of retinol-binding protein and transthyretin in F9 embryonal carcinoma cells differentiated to embryoid bodies. J Biol Chem. 1988; 263: 17897–900.
  • 25
    Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension. 1990; 16: 301–7.
  • 26
    Juul A, Dalgaard P, Blum WF, et al. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab. 1995; 80: 2534–42.
  • 27
    Sabatier JP, Guaydier-Souquieres G, Laroche D, et al. Bone mineral acquisition during adolescence and early adulthood: a study in 574 healthy females. 10–24. years of age. Osteoporos Int. 1996; 6: 141–8.
  • 28
    Bailey DA, McKay HA, Mirwald RL, Crocker PR, Faulkner RA. A six-year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children: the university of Saskatchewan bone mineral accrual study. J Bone Miner Res. 1999; 14: 1672–9.
    Direct Link:
  • 29
    Stratikopoulos E, Szabolcs M, Dragatsis I, Klinakis A, Efstratiadis A. The hormonal action of IGF1 in postnatal mouse growth. Proc Natl Acad Sci U S A. 2008; 105: 19378–83.
  • 30
    Tommasini SM, Hu B, Nadeau JH, Jepsen KJ. Phenotypic integration among trabecular and cortical bone traits establishes mechanical functionality of inbred mouse vertebrae. J Bone Miner Res. 2009; 24: 606–20.
    Direct Link:
  • 31
    Jiang J, Lichtler AC, Gronowicz GA, et al. Transgenic mice with osteoblast-targeted insulin-like growth factor-I show increased bone remodeling. Bone. 2006; 39: 494–504.
  • 32
    Zhang M, Xuan S, Bouxsein ML, et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem. 2002; 277: 44005–12.
  • 33
    Zhao G, Monier-Faugere MC, Langub MC, et al. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology. 2000; 141: 2674–82.
  • 34
    Backeljauw PF, Underwood LE. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome–a clinical research center study. GHIS Collaborative Group. J Clin Endocrinol Metab. 1996; 81: 3312–7.
View Full Article (HTML) Get PDF (338K)